Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LEXICON PHARMACEUTICALS, INC. (LXRX)

Lexicon Pharmaceuticals Q2 net loss $31.8 million vs $3.3 million profit a year earlier

Negative Impact 3 of 5 earnings Written later

Lexicon Pharmaceuticals reported second-quarter 2026 revenue of $0.7 million, down from $28.9 million a year earlier, when licensing revenue from Novo Nordisk was recognized. The company swung to a net loss of $31.8 million, or $0.07 per share, from net income of $3.3 million, or $0.01 per share, in the prior-year quarter, which matters to shareholders because the company reported no licensing revenue this quarter and held $190.6 million in cash and investments at June 30, 2026.

Key points

  • Total revenues were $0.7 million in Q2 2026, versus $28.9 million in Q2 2025, which included $27.6 million in licensing revenue.
  • Net loss was $31.8 million, or $0.07 per share, versus net income of $3.3 million, or $0.01 per share, a year earlier.
  • R&D expenses rose to $17.4 million from $15.7 million, and SG&A expenses rose to $9.8 million from $9.4 million.
  • Cash and investments were $190.6 million as of June 30, 2026; a $100 million Hercules Capital loan facility was entered into in May 2026.

The filing

CompanyLEXICON PHARMACEUTICALS, INC. (LXRX)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:33 AM ET
Accession number0001062822-26-000112

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.